Hikal Ltd Upgraded to Hold by MarketsMOJO Amid Mixed Financial and Technical Signals

Quality Assessment: Weak Long-Term Fundamentals

Hikal’s quality parameters continue to reflect underlying challenges. The company has exhibited a weak long-term fundamental strength, with a compounded annual growth rate (CAGR) of operating profits declining by -25.23% over the past five years. This contraction in core profitability is a significant drag on investor confidence.

Moreover, the company’s ability to service debt remains limited, evidenced by a high Debt to EBITDA ratio of 3.10 times. This elevated leverage ratio raises concerns about financial flexibility and risk, especially in a sector that demands consistent investment in research and development.

Return on Equity (ROE) averages at a modest 7.60%, signalling low profitability per unit of shareholders’ funds. This figure is below industry averages, indicating that the company has struggled to generate adequate returns for equity investors. The flat financial performance in Q1 FY26-27, with a Profit Before Tax (PBT) loss of ₹20.60 crores and a net loss after tax (PAT) of ₹16.30 crores, further underscores the ongoing operational difficulties.

Valuation: Attractive Despite Challenges

Despite the weak fundamentals, Hikal’s valuation metrics present a more favourable picture. The company boasts a Return on Capital Employed (ROCE) of 3%, which, while low, is coupled with an attractive Enterprise Value to Capital Employed (EV/CE) ratio of 2. This suggests that the stock is trading at a discount relative to its capital base and peers’ historical valuations.

Currently priced at ₹243.05, up 9.38% on the day, the stock remains below its 52-week high of ₹282.70 but well above the 52-week low of ₹145.95. This valuation discount may appeal to investors seeking entry points in the Pharmaceuticals & Biotechnology sector, especially given the company’s small-cap status and potential for recovery.

However, it is important to note that over the past year, Hikal’s stock has generated a negative return of -7.25%, underperforming the Sensex benchmark, which declined by -5.67% over the same period. The stock’s five-year return of -62.03% starkly contrasts with the Sensex’s 30.63% gain, highlighting the company’s prolonged underperformance.

Financial Trend: Flat Quarterly Performance Amid Declining Profitability

Hikal’s recent quarterly results for Q1 FY26-27 reveal a flat financial trend with significant deterioration in profitability. The PBT excluding other income plunged by 1398.2% compared to the previous four-quarter average, registering a loss of ₹20.60 crores. Similarly, PAT declined by 279.6% to a loss of ₹16.30 crores.

The company’s half-year ROCE stands at a low 3.66%, indicating limited efficiency in generating returns from capital employed. This flat to negative financial trend has contributed to the cautious stance on the stock, despite some positive technical signals.

Over the last three years, Hikal has consistently underperformed the benchmark indices, including the BSE500, with negative returns in each of the last three annual periods. This persistent underperformance highlights the challenges the company faces in regaining investor trust and market momentum.

Technicals: Bullish Momentum Drives Upgrade

The primary catalyst for the upgrade from Sell to Hold is the marked improvement in technical indicators. The technical grade has shifted from mildly bullish to bullish, signalling a positive change in market sentiment and price momentum.

Key technical metrics supporting this upgrade include:

• MACD: Weekly readings are bullish, while monthly remain mildly bullish, indicating strengthening momentum in the short term.
• Moving Averages: Daily moving averages are bullish, reinforcing the upward price trend.
• Bollinger Bands: Weekly bands show bullish signals, although monthly bands remain mildly bearish, suggesting some caution in longer-term volatility.
• KST (Know Sure Thing): Weekly KST is bullish, but monthly KST is bearish, reflecting mixed signals over different time frames.
• Dow Theory: Weekly trend is mildly bullish, while monthly shows no clear trend.
• On-Balance Volume (OBV): Monthly OBV is bullish, indicating accumulation by investors over the medium term.

These technical improvements have coincided with a strong recent price performance, with the stock gaining 20.47% over the past week compared to a 1.07% decline in the Sensex. Over the past month, Hikal has risen 7.05%, while the Sensex fell 3.01%, further highlighting the stock’s relative strength.

Comparative Returns and Market Context

While Hikal’s short-term technical momentum is encouraging, its long-term returns remain subdued. The stock’s 10-year return of 101.08% lags behind the Sensex’s 163.19%, and its three-year return of -22.91% contrasts sharply with the Sensex’s 14.89% gain. This disparity emphasises the need for investors to weigh technical optimism against fundamental weaknesses.

Hikal’s market capitalisation classifies it as a small-cap stock, which typically entails higher volatility and risk. The company’s promoter holding remains majority, which can be a stabilising factor but also requires scrutiny regarding governance and strategic direction.

Conclusion: Hold Rating Reflects Balanced View

The upgrade of Hikal Ltd’s investment rating to Hold from Sell reflects a nuanced assessment balancing improved technical momentum against persistent fundamental weaknesses. While the company’s financial performance remains under pressure, the attractive valuation and bullish technical signals provide a rationale for cautious optimism.

Investors should remain mindful of the company’s weak profitability metrics, high leverage, and consistent underperformance relative to benchmarks. However, the recent price strength and technical indicators suggest potential for a stabilisation or recovery phase in the near term.

Given these factors, the Hold rating is appropriate for investors seeking exposure to the Pharmaceuticals & Biotechnology sector with a moderate risk appetite, while those prioritising strong fundamentals may prefer to explore alternative opportunities.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today